Score Overview
Explore the 2021 public Archive ranking →
Where Harvard Bioscience Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- HBIO
2006: 61.9% · 2021: 80.0% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 7.92 | — |
1 Year2025-09-30 | $ 4.38 | 80.62% |
5 Years2021-09-30 | $ 69.80 | -88.65% |
10 Years2016-09-30 | $ 27.20 | -70.88% |
20 Years2006-09-29 | $ 34.09 | -76.77% |
All Time2000-12-07 | $ 79.55 | -90.04% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-09-29 | All Time2000-12-07 |
|---|---|---|---|---|---|---|
| Price | $ 7.92 | $ 4.38 | $ 69.80 | $ 27.20 | $ 34.09 | $ 79.55 |
| Return | — | 80.62% | -88.65% | -70.88% | -76.77% | -90.04% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 87M | -$ 10M | $ 6M |
| 2025 | $ 86M | -$ 56M | $ 8M |
| 2024 | $ 94M | -$ 12M | $ 4M |
| 2023 | $ 112M | -$ 3M | $ 4M |
| 2022 | $ 113M | -$ 9M | $ 4M |
| 2021 | $ 118M | -$ 288K | $ 7M |
| 2020 | $ 102M | -$ 7M | $ 8M |
| 2019 | $ 116M | -$ 4M | $ 8M |
| 2018 | $ 120M | -$ 3M | $ 8M |
| 2017 | $ 101M | -$ 865K | $ 5M |
| 2016 | $ 104M | -$ 4M | $ 5M |
| 2015 | $ 108M | -$ 19M | $ 6M |
| 2014 | $ 108M | $ 2M | $ 14M |
| 2013 | $ 105M | -$ 1M | $ 25M |
| 2012 | $ 111M | $ 2M | $ 20M |
| 2011 | $ 108M | $ 3M | $ 17M |
| 2010 | $ 108M | $ 19M | $ 19M |
| 2009 | $ 85M | $ 7M | $ 16M |
| 2008 | $ 88M | $ 1M | $ 13M |
| 2007 | $ 83M | -$ 1M | $ 17M |
| 2006 | $ 76M | -$ 2M | $ 9M |
| 2005 | $ 67M | -$ 31M | $ 7M |
| 2004 | $ 92M | $ 2M | $ 13M |
| 2003 | $ 87M | $ 4M | $ 8M |
| 2002 | $ 57M | $ 737.33K | $ 15M |
| 2001 | $ 40M | -$ 5M | $ 29M |
| IPO2000 | $ 30M | -$ 49M | $ 35M |
Harvard Bioscience Inc fundamental performance
Between 2015 and 2025, revenue declined from $ 108M to $ 86M and net income went from -$ 19M to -$ 56M. Revenue increased in 3 of those 10 years; net income in 4.
Across Harvard Bioscience Inc's full reported history, from 2000 to 2025, revenue grew from $ 30M to $ 86M and net income went from -$ 49M to -$ 56M. Revenue increased in 58% of the years measured; net income in 54%.
Harvard Bioscience Inc currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.
Membership
Continue HBIO’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
